EPS for Acceleron Pharma Inc. (XLRN) Expected At $-0.69; Compx International (NYSEAMERICAN:CIX) Shorts Raised By 1.67%

Acceleron Pharma Inc. (NASDAQ:XLRN) Logo

Analysts expect Acceleron Pharma Inc. (NASDAQ:XLRN) to report $-0.69 EPS on May, 14.They anticipate $0.11 EPS change or 18.97% from last quarter’s $-0.58 EPS. After having $-0.75 EPS previously, Acceleron Pharma Inc.’s analysts see -8.00% EPS growth. The stock decreased 2.74% or $1.23 during the last trading session, reaching $43.51. About 167,014 shares traded. Acceleron Pharma Inc. (NASDAQ:XLRN) has risen 13.86% since April 11, 2018 and is uptrending. It has outperformed by 9.49% the S&P500. Some Historical XLRN News: 26/04/2018 – Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting; 30/04/2018 – Acceleron to Webcast First Quarter 2018 Operating and Financial Results on May 8, 2018; 12/03/2018 Acceleron to Host Educational Webinar with Leading Clinicians to Provide an Overview of Pulmonary Arterial Hypertension (PAH); 01/05/2018 – Acceleron Receives FDA Fast Track Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy (FSHD); 08/05/2018 – ACCELERON 1Q LOSS/SHR 58C, EST. LOSS/SHR 65C; 07/05/2018 – Acceleron at Deutsche Bank Health Care Conference Tomorrow; 08/05/2018 – Acceleron Pharma 1Q Loss/Shr 58c; 19/03/2018 – CAFC: DELL INC. v. ACCELERON, LLC [OPINION] – Appeal #17-1101 – 2018-03-19; 09/05/2018 – ACCELERON PHARMA INC XLRN.O : LEERINK RAISES TARGET PRICE TO $68 FROM $65; 01/05/2018 – ACCELERON GETS FDA FAST TRACK FOR ACE-083 IN FSHD

Compx International Inc (NYSEAMERICAN:CIX) had an increase of 1.67% in short interest. CIX’s SI was 6,100 shares in April as released by FINRA. Its up 1.67% from 6,000 shares previously. With 1,700 avg volume, 4 days are for Compx International Inc (NYSEAMERICAN:CIX)’s short sellers to cover CIX’s short positions. The SI to Compx International Inc’s float is 0.37%. The stock increased 0.76% or $0.12 during the last trading session, reaching $15.33. About 1,662 shares traded. CompX International Inc. (NYSEAMERICAN:CIX) has risen 4.30% since April 11, 2018 and is uptrending. It has underperformed by 0.07% the S&P500. Some Historical CIX News: 07/05/2018 – CompX International 1Q EPS 30c; 23/05/2018 – REG-COMPX ANNOUNCES REGULAR QUARTERLY DIVIDEND AND RESULTS OF THE ANNUAL STOCKHOLDER MEETING; 20/04/2018 DJ CompX International Inc Class A, Inst Holders, 1Q 2018 (CIX)

Since December 4, 2018, it had 1 buy, and 5 insider sales for $28.86 million activity. 5,712 shares valued at $244,494 were sold by MCLAUGHLIN KEVIN F on Wednesday, January 2. Another trade for 5,788 shares valued at $248,546 was made by Kumar Ravindra on Wednesday, January 2. $254,490 worth of stock was sold by Quisel John D on Wednesday, January 2. CELGENE CORP /DE/ had bought 706,206 shares worth $30.37 million. The insider Dable Habib J sold 1,957 shares worth $84,961.

Investors sentiment increased to 1.11 in 2018 Q4. Its up 0.08, from 1.03 in 2018Q3. It improved, as 19 investors sold Acceleron Pharma Inc. shares while 43 reduced holdings. 26 funds opened positions while 43 raised stakes. 42.51 million shares or 0.49% less from 42.72 million shares in 2018Q3 were reported. Envestnet Asset Incorporated owns 0% invested in Acceleron Pharma Inc. (NASDAQ:XLRN) for 5,695 shares. Sectoral Asset Mngmt stated it has 1.25% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN). Bnp Paribas Arbitrage Sa holds 0% or 869 shares in its portfolio. 53,000 are owned by State Of New Jersey Common Pension Fund D. Bank Of Montreal Can has 1,684 shares. 16,608 were accumulated by Legal & General Group Public Ltd Company. Farallon Cap Limited Co reported 2.10M shares. Tekla Cap Mgmt Ltd Liability Corp has invested 0.32% in Acceleron Pharma Inc. (NASDAQ:XLRN). Great Point Ptnrs Limited Co holds 5.71% of its portfolio in Acceleron Pharma Inc. (NASDAQ:XLRN) for 1.04M shares. Moreover, Bamco New York has 0.02% invested in Acceleron Pharma Inc. (NASDAQ:XLRN). Eventide Asset Mgmt Lc owns 128,900 shares. Dekabank Deutsche Girozentrale reported 0.06% in Acceleron Pharma Inc. (NASDAQ:XLRN). Perceptive Advsr Ltd Liability Corp stated it has 905,017 shares. Nelson Van Denburg And Campbell Wealth Mngmt Gru Ltd Liability, Nebraska-based fund reported 4,090 shares. Platinum Investment stated it has 0.08% in Acceleron Pharma Inc. (NASDAQ:XLRN).

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for serious and rare diseases. The company has market cap of $2.25 billion. The Company’s therapeutic candidates include luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia; and sotatercept for chronic kidney diseases. It currently has negative earnings. The company's therapeutic candidates also include dalantercept, a tyrosine kinase inhibitor, which is in phase II clinical trials for renal cell carcinoma; and ACE-083 that is in phase II clinical trials for facioscapulohumeral dystrophy.

More notable recent Acceleron Pharma Inc. (NASDAQ:XLRN) news were published by: Nasdaq.com which released: “Bullish Two Hundred Day Moving Average Cross – XLRN – Nasdaq” on March 21, 2019, also Seekingalpha.com with their article: “Acceleron bails on early-stage candidate; shares down 4% after hours – Seeking Alpha” published on April 04, 2019, Streetinsider.com published: “Celgene (CELG), Acceleron Pharma (XLRN) Announce Submission of Luspatercept BLA to US FDA – StreetInsider.com” on April 05, 2019. More interesting news about Acceleron Pharma Inc. (NASDAQ:XLRN) were released by: Benzinga.com and their article: “Geron’s Blood Cancer Candidate Creates Buying Opportunity, Needham Says In Upgrade (NASDAQ:GERN) – Benzinga” published on April 09, 2019 as well as Nasdaq.com‘s news article titled: “Celgene & Acceleron Submit BLA for Luspatercept to the FDA – Nasdaq” with publication date: April 08, 2019.

Among 2 analysts covering Acceleron Pharma (NASDAQ:XLRN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Acceleron Pharma had 3 analyst reports since February 26, 2019 according to SRatingsIntel. H.C. Wainwright maintained the shares of XLRN in report on Tuesday, February 26 with “Buy” rating. H.C. Wainwright maintained the shares of XLRN in report on Tuesday, March 5 with “Buy” rating.

Investors sentiment decreased to 1.44 in Q4 2018. Its down 0.12, from 1.56 in 2018Q3. It dropped, as 1 investors sold CompX International Inc. shares while 8 reduced holdings. 3 funds opened positions while 10 raised stakes. 1.35 million shares or 0.55% more from 1.34 million shares in 2018Q3 were reported. Horrell Inc reported 10,000 shares. Wells Fargo Company Mn, a California-based fund reported 265 shares. Barclays Pcl holds 0% or 48 shares in its portfolio. California State Teachers Retirement holds 0% or 2,524 shares in its portfolio. Moreover, Renaissance Technologies Ltd Com has 0% invested in CompX International Inc. (NYSEAMERICAN:CIX). Moreover, Northern Tru Corporation has 0% invested in CompX International Inc. (NYSEAMERICAN:CIX). Tower Capital Ltd Com (Trc) accumulated 103 shares. California Pub Employees Retirement Sys owns 16,595 shares for 0% of their portfolio. Moreover, Ny State Common Retirement Fund has 0% invested in CompX International Inc. (NYSEAMERICAN:CIX). Deutsche National Bank Ag reported 0% in CompX International Inc. (NYSEAMERICAN:CIX). Legal And General Group Inc Public Limited Company owns 135 shares. Minerva Advisors Ltd reported 17,048 shares. Blackrock reported 109,264 shares. Royal Bank Of Canada reported 0% of its portfolio in CompX International Inc. (NYSEAMERICAN:CIX). Fmr Ltd Liability Corporation reported 462 shares.

CompX International Inc. (NYSEAMERICAN:CIX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.